glp-1 receptor agonists cardiovascular benefits The effects of beyond obesity and type 2 diabetes: An anti-atherosclerotic action The Many Cardiovascular Benefits of

[DOI] [PubMed] [Google Scholar] 17.Wu F., Klapman S.A., Everett L.L., Kuo B., Hobai I.A

GLP-1 agonists also reduced headache risk, with the most significant effect at 3 months (RR: 0.69), remaining statistically significant at 6, 12, and 24 months

For instance, semaglutide has been approved and is being researched for indications including obesity, T2DM, reducing cardiovascular risk, chronic kidney disease, NAFLD, and AD, indicating that the development of new indications could provide new growth opportunities for GLP-1 drugs

We care about facts, not blame

Pre-clinical studies showed that anti-atherogenic effect of GLP-1 is independent of modulation of plasma lipid levels and depends on anti-inflammatory response